Oluyemi Okupe plans $1.1M Hims share sale

Issuer: HIMS Holdings Corp. Reported Form 144 notices show multiple sales of Common stock by Oluyemi Okupe, executed on various dates in April–June 2026.

Rhea-AI Filing Summary

Issuer: HIMS Holdings Corp. Reported Form 144 notices show multiple sales of Common stock by Oluyemi Okupe, executed on various dates in April–June 2026. Individual transactions range from 1,438 shares to 55,383 shares, with corresponding proceeds shown in the filing.

The filing indicates some shares were acquired as compensation via stock options and disposed via cashless exercise / same-day sale. Dates and per-transaction proceeds are listed for each sale in the excerpt.

Insights

Equity Compensation Specialist

Multiple option-derived dispositions by a single holder, executed across April–June 2026.

These entries list numerous disposals by Oluyemi Okupe, many described as resulting from cashless exercises or same-day sales. The filing shows per-transaction share counts and gross proceeds but does not state post-transaction holdings in the excerpt.

Cash-flow treatment appears as proceeds to the selling holder; timing and any Rule 10b5-1 plan references are not present in the provided text, so further filings or footnotes would be needed for pre-arrangement context.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does HIMS (HIMS) Form 144 report about Oluyemi Okupe?

The filing reports multiple sales of Common stock by Oluyemi Okupe on dates in April–June 2026. Each transaction lists the number of shares sold and gross proceeds; some disposals stem from stock options exercised as compensation.

How large were the largest sales reported on the Form 144?

The largest single transaction shown is 55,383 shares with proceeds of $1,943,389.47. Other large entries include 36,922 shares for $956,146.88 and 12,553 shares for $376,207.13 as listed in the excerpt.

Do the Form 144 entries say why the shares were sold?

Some shares are identified as acquired as compensation—stock options and disposed via cashless exercise / same-day sale. The excerpt does not provide additional reasons, such as personal liquidity needs or pre-arranged trading plans.

Does the Form 144 state whether HIMS received proceeds from these sales?

The transactions shown are disposals by the reporting holder and list gross proceeds per trade. The excerpt does not state that HIMS received proceeds; the entries indicate proceeds attributable to the selling holder.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/06/2026 - 06:17 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001907056
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Hims & Hers Health, Inc.
SEC File Number	001-38986
Address of Issuer	2269 Chestnut Street Suite 523 San Francisco CALIFORNIA 94123
Phone	1-415-851-0195
Name of Person for Whose Account the Securities are To Be Sold	Oluyemi Okupe
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Goldman Sachs & Co. LLC 200 West Street New York NY 10282	28652	1096798.56	223080072	07/06/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/24/2022	Acquired as compensation -- Stock Options	Issuer			28652	02/24/2022	Compensation -- Cashless exercise / same-day sale

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Oluyemi Okupe 2269 Chestnut Street Suite 523 San Francisco CA 94123	Common	05/18/2026	7950	187915.74
Oluyemi Okupe 2269 Chestnut Street Suite 523 San Francisco CA 94123	Common	04/06/2026	3975	79408.57
Oluyemi Okupe 2269 Chestnut Street Suite 523 San Francisco CA 94123	Common	06/22/2026	5911	200460.93
Oluyemi Okupe 2269 Chestnut Street Suite 523 San Francisco CA 94123	Common	04/17/2026	3975	110229.13
Oluyemi Okupe 2269 Chestnut Street Suite 523 San Francisco CA 94123	Common	06/22/2026	3546	120616.13
Oluyemi Okupe 2269 Chestnut Street Suite 523 San Francisco CA 94123	Common	06/22/2026	2364	79729.68
Oluyemi Okupe 2269 Chestnut Street Suite 523 San Francisco CA 94123	Common	04/17/2026	2209	61760.33
Oluyemi Okupe 2269 Chestnut Street Suite 523 San Francisco CA 94123	Common	04/17/2026	11821	329167.57
Oluyemi Okupe 2269 Chestnut Street Suite 523 San Francisco CA 94123	Common	04/16/2026	36922	956146.88
Oluyemi Okupe 2269 Chestnut Street Suite 523 San Francisco CA 94123	Common	04/20/2026	7092	212408.95
Oluyemi Okupe 2269 Chestnut Street Suite 523 San Francisco CA 94123	Common	04/20/2026	12553	376207.13
Oluyemi Okupe 2269 Chestnut Street Suite 523 San Francisco CA 94123	Common	06/22/2026	1438	48892
Oluyemi Okupe 2269 Chestnut Street Suite 523 San Francisco CA 94123	Common	06/22/2026	4938	169518.08
Oluyemi Okupe 2269 Chestnut Street Suite 523 San Francisco CA 94123	Common	06/18/2026	55383	1943389.47

144: Remarks and Signature

Remarks	The sales of shares set forth herein are made in connection with a selling plan dated 5/21/2025, that is intended to comply with Rule 10b5-1(c).
Date of Notice	07/06/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/21/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Goldman Sachs & Co. LLC on behalf of Oluyemi Okupe
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)